DDInter655 DDInter1676
An anthracycline which is the 4&#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Epirubicin {u} (Compound) treats {v} (Disease) ovarian cancer
Epirubicin {u} (Compound) binds {v} (Gene) YWHAG
Epirubicin {u} (Compound) upregulates {v} (Gene) SCPEP1
Epirubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Epirubicin {u} (Compound) downregulates {v} (Gene) KPNA2
Epirubicin {u} (Compound) causes {v} (Side Effect) Haemoptysis
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Epirubicin (Compound) resembles Doxorubicin (Compound)
Epirubicin (Compound) resembles Valrubicin (Compound)
Epirubicin (Compound) treats ovarian cancer (Disease)
Epirubicin (Compound) binds YWHAG (Gene)
Epirubicin (Compound) upregulates SCPEP1 (Gene)
Epirubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Epirubicin (Compound) downregulates KPNA2 (Gene)
Epirubicin (Compound) causes Haemoptysis (Side Effect)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin